Metabolism and mechanism of action of 5-fluorouracil

doi:10.1016/0163-7258(90)90056-8

Pharmacology & Therapeutics

Volume 48, Issue 3, 1990, Pages 381-395

https://doi.org/10.1016/0163-7258(90)90056-8 Get rights and content

Abstract

This is a review on the mechanism of action of FUra. Three main areas are addressed: metabolism,RNA-directed actions of FUra, and DNA-directed actions of FUra. Key words for bibliographic purposes: metabolism, RNA, rRNA, mRNA, tRNA, DNA primase, DNA, thylidylate synthetase, uracil N-glycosylase, FUra, FUrd, FdUrd, FdUMP, RNA splicing, 5,10-methylene tetrahydrofolate, FUTP.

References (133)

B. Ardalan et al.
An update on the biochemistry of 5-fluorouracil
Cancer Treat. Rep.
(1981)
B. Ardalan et al.
Synergic efefct of 5-fluorouracil and $N-(phosphonacetyl)- l -asparatate$ on cell growth and ribonucleic acid synthesis in a human mammary carcinoma
Biochem. Pharmac.
(1981)
R.D. Armstrong et al.
Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism
J. biol. Chem.
(1986)
R.D. Armstrong et al.
Fluoropyrimidine-mediated changes in small nuelcars RNA
J. biol. Chem.
(1986)
J.P. Brown et al.
The identification of the forms of folate found in the liver, kidney, and intestine of the monkey and their biosynthesis for pteroyglutamate (folic acid)
Biochim. biophys. Acta
(1974)
E. Cadman et al.
The influence of methotrexate on 5-fluorouracil metabolism in L1210 cells
J. biol. Chem.
(1981)
S.J. Caradonna et al.
Uracil DNA-glycosylase. Purification and properties of this enzyme isolated from blast cells of acute myelocytic leukemia patients
J. biol. Chem.
(1980)
R. Cone et al.
Inhibitor of uracil-DNA glycosylase induced by bacteriophage PBS2. Purification and preliminary characterization
J. biol. Chem.
(1980)
P.V. Danenberg
Thymidylate synthetase—A target enzyme in cancer chemotherapy
Biochim. biophys. Acta
(1977)
P.V. Danenberg et al.
Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase
Pharmac. Ther.
(1981)

P.V. Danenberg et al.

The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cells

Biochem. biophys. Res. Commun.

(1981)

B.J. Dolnick et al.

Human thymidylate synthetase. II. Derivatives of pterolmono- and polyglutamates as substrates and inhibitors

J. biol. Chem.

(1978)

B.J. Dolnick et al.

5-fluorouracil modulation of dihydrofolate reductase RNA levels in methotrexate-resistant KB cells

J. biol. Chem.

(1983)

B.J. Dolnick et al.

Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells

J. biol. Chem.

(1985)

S.L. Doong et al.

5-Fluorouracil substitution alters pre-mRNA splicing in vitro

J. biol. Chem.

(1988)

I. Eto et al.

Determination of three different pools of reduced one-carbon-substituted folates II. Quantitation and chain-length determination of the pteroylpolyglutamates of rat liver

Analyt. Biochem.

(1981)

S.K. Foo et al.

Regulation of folypoly-gamma-glutamine synthesis in mammalian cells. In vitro and vivo synthesis of pteroylpoly-gamma-glutamates by chinese hamster ovary cells

J. biol. Chem.

(1982)

J.L. Grem et al.

Ehnacement of 5-fluorouracil's anticancer activity by dipyridamollle

Pharmac. Ther.

(1989)

L. Grossman

Enzymes involved in the repair of damaged DNA

Archs Biochem. Biophys.

(1981)

I. Kaiser et al.

Identification of 5-fluorocytidine in RNA from Escherichia coli grown in the presence of 5-fluorouracil

FEBS Lett.

(1973)

K. Keyomarsi et al.

Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid mouse leukemic cells

J. biol. Chem.

(1988)

P. Klubes et al.

Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue

Pharmac. Ther.

(1989)

D.W. Kufe et al.

Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid

Biochem. Pharmac.

(1981)

D.W. Kufe et al.

5-fluoro-2′-deoxyuridine incorporation in L1210 DNA

J. biol. Chem.

(1981)

D.W. Kufe et al.

Biological effect of 5-fluoro-2′-deoxyuridine incorporation in L1210 deoxyribonucleic acid

Biochem. Pharmac.

(1983)

U. Lonn et al.

The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil

Biochem. Pharmac.

(1986)

E. Mini et al.

Enhancement of the antitumor effects of 5-fluorouracil by folinic acid

Pharmac. Ther.

(1990)

D. Nakada et al.

The roles of inducer and catabolite repressor in the synthesis of β-galactosidase by Escherichia coli

J. molec. Biol.

(1964)

M.S. Peterson et al.

2′-Deoxyribosyl analogues of UDP-N-acetylglucosamine in cells treated with methotrexate or 5-fluorodeoxyuridine

J. biol. Chem.

(1983)

A.L. Pogolotti et al.

Methods for the complete analysis of 5-fluorouracil metabolites in cell extracts

Analyt. Biochem.

(1981)

R.D. Armstrong et al.

Alterations in messenger RNA and small nuclear RNA metabolism resulting from fluorouracil incorporation

S.H. Berger et al.

Thymidylate synthase as a determinant of 5-fluoro-2′-deoxyuridine response in human colonic tumoor cell lines

Molec. Pharmac.

(1988)

S.H. Berger et al.

A naturally occuring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′deoxyuridine in ahuman colon tumor cell line

Molec. Pharmac.

(1988)

D.A. Boothman et al.

Metabolic channeling of 5-fluoro-2′-deoxycytidine utilizing inhibitors of its deamination in cell culture

Molec. Pharmac.

(1985)

D.A. Boothman et al.

Protective, tumor-selective dual pathway activation of 5-fluoro-2′-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755

Cancer Res.

(1987)

D.A. Boothman et al.

Tumor-selective metabolism of 5-fluoro-2′-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil mice bearing lewis lung carcinoma

Cancer Res.

(1987)

S.J. Caradonna et al.

The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells

Molec. Pharmac.

(1980)

Fluorinated pyrimidines

Y.C. Cheng et al.

Effects of 5-fluoro-2′-deoxyuridine on DNA metabolism in HeLa cells

Molec. Pharmac.

(1983)

R.R. Cummins et al.

Activities of some enzymes of pyrimidine and DNA synthesis in a rat transplantable hepatoma and human primarily hepatomas, in cell lines derived from these tissues and in human fetal liver

Cancer Res.

(1980)

P.V. Danenberg et al.

Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism

Biochemistry

(1978)

P.V Danenberg et al.

Thymidylate synthetase-substrate complex formation

Molec. cell. Biochem.

(1982)

P.V. Danenberg et al.

Effect of 5-fluorouracil substitution on the self-splicing activity of Tetrahymena of ribosomal RNA

Cancer Res.

(1990)

S.T. Davis et al.

Modulation of 5-fluoro-2′-deoxyuridine response by folinic acid in human colonic tumor cell lines: The role of thymidylate sythase

Molec. Pharmac.

(1989)

R.B. Diasio et al.

Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells

Canceer Res.

(1985)

R.M. Evans et al.

Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells

Cancer Res.

(1980)

R.M. Evans et al.

Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil on the activity and site of action of 5-fluorouracil

Cancer Res.

(1981)

D.J. Fernandes et al.

5-fluorouracil-methotrexate synergy: Enhancement of 5-fluorodeoxy-uridylate binding to thymidylate synthase by dihydropteroylpolyglutamates

D.J. Fernandes et al.

Dissociation of thymidylate biosynthesis from DNA biosynthesis by 5-fluoro-2′-deoxyuridine and 5,8-dideazaisofolic acid

Cancer Res.

(1986)

R.I. Glazer et al.

Analysis of the effect of 5-fluorouracil on the synthesis and translation of polysomal poly(A)RNA from Ehrlich ascites cells

Molec. Pharmac.

(1981)

Cited by (414)

Induction of breast cancer cell apoptosis by novel thiouracil-fused heterocyclic compounds through boosting of Bax/Bcl-2 ratio and DFT study
2024, Bioorganic Chemistry
Breast cancer is a common public health disease causing mortality worldwide. Thus, providing novel chemotherapies that tackle breast cancer is of great interest. In this investigation, novel pyrido[2,3-d]pyrimidine derivatives 3,4,(6a-c),(8a,b),9–20 were synthesized and characterized using a variety of spectrum analyses. The geometric and thermal parameters of the novel thiouracil derivatives 3,4,6a,(8a,b),11,12,17,18, 19 were measured using density functional theory (DFT) via DFT/B3LYP/6–31 + G(d,p) basis set. All synthesized compounds were evaluated by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) method using MCF-7 and MDA-MB-231 breast cancerous cells, compound 17 had the maximum anticancer activity against both breast cancerous cells, recording the lowest half-maximal inhibitory concentration (IC50) values (56.712 μg/mL for MCF-7 cells and 48.743 μg/mL for MDA-MB-231 cells). The results were confirmed in terms of the intrinsic mechanism of apoptosis, where compound 17 had the highest percentage in the case of both cancer cells and recorded Bax (Bcl-2 associated X)/Bcl-2 (B-cell lymphoma 2) ratio 17.5 and 96.667 for MCF-7 and MDA-MB-231 cells, while compound 19 came after 17 in the ability for induction of apoptosis, where the Bax/Bcl-2 ratio was 15.789 and 44.273 for both cancerous cells, respectively. Also, compound 11 recorded a high Bax/Bcl-2 ratio for both cells. The safety of the synthesized compounds was applied on normal WI-38 cells, showing minimum cytotoxic effect with undetectable IC50. Compounds 17, 11, and 19 recorded a significant increase of p53 upregulated modulator of apoptosis (PUMA) expression levels in the cancerous cells. The DFT method was also used to establish a connection between the experimentally determined values of the present investigated compounds and their predicted quantum chemical parameters. It was concluded that Compounds 17, 11, and 19 had anti-breast cancer potential through the induction of apoptotic Bax/Bcl-2 and PUMA expression levels.
Facile electrochemical determination of 5-fluorouracil as an important anti-cancer drug using CeO<inf>2</inf>–CuO nanocomposite modified carbon paste electrode
2024, Materials Chemistry and Physics
In this study, a carbon paste electrode was modified with a composite material of CeO₂–CuO to fabricate an electrochemical sensor. The fabricated sensor was then employed for the analysis of 5-fluorouracil (5-FU), an important anticancer drug, in a phosphate buffer solution (PBS) with pH 7.0, using cyclic voltammetry (CV) and differential potential voltammetry (DPV) techniques. The effect of critical parameters such as catalyst loading, scan rate, type, and pH of the supporting electrolyte on the electrochemical responses of the modified electrode was assessed and optimized. The electrochemical response of the fabricated sensor towards 5-FU remained unaffected in the presence of various potent interfering compounds, indicating its anti-interference capability. The DPV responses of the prepared sensor was linear with the concentration of 5-FU in the range of 0.1–1.0 μmol L⁻¹ and 1.0–40.0 μmol L⁻¹ under optimal experimental conditions, with a detection limit of 0.01 μmol L⁻¹. The electrochemical sensor developed in this study was employed to determine 5-FU in human urine samples with the acceptable recovery. The fabricated sensor demonstrated favorable characteristics such as high sensitivity, repeatability, reproducibility, and stability.
Nucleoside-based anticancer drugs: Mechanism of action and drug resistance
2023, Biochemical Pharmacology
Nucleoside-based drugs, recognized as purine or pyrimidine analogs, have been potent therapeutic agents since their introduction in 1950, deployed widely in the treatment of diverse diseases such as cancers, myelodysplastic syndromes, multiple sclerosis, and viral infections. These antimetabolites establish complex interactions with cellular molecular constituents, primarily via activation of phosphorylation cascades leading to consequential interactions with nucleic acids. However, the therapeutic efficacy of these agents is frequently compromised by the development of drug resistance, a continually emerging challenge in their clinical application. This comprehensive review explores the mechanisms of resistance to nucleoside-based drugs, encompassing a wide spectrum of phenomena from alterations in membrane transporters and activating kinases to changes in drug elimination strategies and DNA damage repair mechanisms. The critical analysis in this review underlines complex interactions of drug and cell and also guides towards novel therapeutic strategies to counteract resistance. The development of targeted therapies, novel nucleoside analogs, and synergistic drug combinations are promising approaches to restore tumor sensitivity and improve patient outcomes.
Martynoside rescues 5-fluorouracil-impaired ribosome biogenesis by stabilizing RPL27A
2023, Science Bulletin
Martynoside (MAR), a bioactive component in several well-known tonic traditional Chinese herbs, exhibits pro-hematopoietic activity during 5-fluorouracil (5-FU) treatment. However, the molecular target and the mechanism of MAR are poorly understood. Here, by adopting the mRNA display with a library of even-distribution (md-LED) method, we systematically examined MAR-protein interactions in vitro and identified the ribosomal protein L27a (RPL27A) as a key cellular target of MAR. Structural and mutational analysis confirmed the specific interaction between MAR and the exon 4,5-encoded region of RPL27A. MAR attenuated 5-FU-induced cytotoxicity in bone marrow nucleated cells, increased RPL27A protein stability, and reduced the ubiquitination of RPL27A at lys92 (K92) and lys94 (K94). Disruption of MAR binding at key residues of RPL27A completely abolished the MAR-induced stabilization. Furthermore, by integrating label-free quantitative ubiquitination proteomics, transcriptomics, and ribosome function assays, we revealed that MAR restored RPL27A protein levels and thus rescued ribosome biogenesis impaired by 5-FU. Specifically, MAR increased mature ribosomal RNA (rRNA) abundance, prevented ribosomal protein degradation, facilitated ribosome assembly, and maintained nucleolar integrity. Collectively, our findings characterize the target of a component of Chinese medicine, reveal the importance of ribosome biogenesis in hematopoiesis, and open up a new direction for improving hematopoiesis by targeting RPL27A.
Stress granules dynamics and promising functions in pancreatic cancer
2023, Biochimica et Biophysica Acta - Reviews on Cancer
Stress granules (SGs), non-membrane subcellular organelles made up of non-translational messenger ribonucleoproteins (mRNPs), assemble in response to various environmental stimuli in cancer cells, including pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC) which has a low 5-year survival rate of 10%. The pertinent research on SGs and pancreatic cancer has not, however, been compiled. In this review, we talk about the dynamics of SGs and their positive effects on pancreatic cancer such as SGs promote PDAC viability and repress apoptosis, meanwhile emphasizing the connection between SGs in pancreatic cancer and signature mutations such KRAS, P53, and SMAD4 as well as the functions of SGs in antitumor drug resistance. This novel stress management technique may open the door to better treatment options in the future.
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
2022, ESMO Open
5-fluorouracil (5-FU) combined with a folate remains an essential treatment component for metastatic colorectal cancer (mCRC). Leucovorin is the folate most often used, but requires intracellular conversion to a reduced folate, and has high pharmacokinetic variability and limited bioavailability in patients with low folate pathway gene expression. Arfolitixorin is an immediately active form of folate, [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF), and may improve outcomes.
This open-label, multicenter, phase I/II study in patients with mCRC (NCT02244632) assessed the tolerability and efficacy of first- or second-line arfolitixorin (30, 60, 120, or 240 mg/m² intravenous) with 5-FU alone, or in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan, every 14 days. Safety, efficacy, and pharmacokinetics were assessed before and after four cycles (8 weeks) of treatment.
In 105 treated patients, investigators reported 583 adverse events (AEs) in 86 patients (81.9%), and 256 AEs (43.9%) were potentially related to arfolitixorin and 5-FU. Dose adjustments were required in 16 patients (15.2%). At 8 weeks, 9 out of 57 patients assessed for efficacy achieved an objective response (15.8%), and all 9 achieved a partial response. Six of these nine patients had received arfolitixorin as a first-line treatment. A further 33 patients (57.9%) achieved stable disease. Pharmacokinetics were assessed in 35 patients. The average t_max was 10 min, and area under the plasma concentration–time curve from time 0 to 1 h increased linearly between 30 and 240 mg/m². No accumulation was observed for [6R]-MTHF following repeated administration, and there were no major pharmacokinetic differences between cycle 1 and cycle 4 at any dose.
Arfolitixorin is a well-tolerated moderator of 5-FU activity. It is suitable for further investigation in mCRC and has the potential to improve treatment outcomes in patients with low folate pathway gene expression. Arfolitixorin can easily be incorporated into current standard of care, requiring minimal changes to chemotherapy regimens.

View all citing articles on Scopus

View full text

Metabolism and mechanism of action of 5-fluorouracil

Abstract

Cancer Treat. Rep.

Biochem. Pharmac.

J. biol. Chem.

J. biol. Chem.

Biochim. biophys. Acta

J. biol. Chem.

J. biol. Chem.

J. biol. Chem.

Biochim. biophys. Acta

Pharmac. Ther.

Biochem. biophys. Res. Commun.

J. biol. Chem.

J. biol. Chem.

J. biol. Chem.

J. biol. Chem.

Analyt. Biochem.

J. biol. Chem.

Pharmac. Ther.

Archs Biochem. Biophys.

FEBS Lett.

J. biol. Chem.

Pharmac. Ther.

Biochem. Pharmac.

J. biol. Chem.

Biochem. Pharmac.

Biochem. Pharmac.

Pharmac. Ther.

J. molec. Biol.

J. biol. Chem.

Analyt. Biochem.

Alterations in messenger RNA and small nuclear RNA metabolism resulting from fluorouracil incorporation

Thymidylate synthase as a determinant of 5-fluoro-2′-deoxyuridine response in human colonic tumoor cell lines

Molec. Pharmac.

A naturally occuring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′deoxyuridine in ahuman colon tumor cell line

Molec. Pharmac.

Metabolic channeling of 5-fluoro-2′-deoxycytidine utilizing inhibitors of its deamination in cell culture

Molec. Pharmac.

Protective, tumor-selective dual pathway activation of 5-fluoro-2′-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755

Cancer Res.

Tumor-selective metabolism of 5-fluoro-2′-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil mice bearing lewis lung carcinoma

Cancer Res.

The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells

Molec. Pharmac.

Fluorinated pyrimidines

Effects of 5-fluoro-2′-deoxyuridine on DNA metabolism in HeLa cells

Molec. Pharmac.

Activities of some enzymes of pyrimidine and DNA synthesis in a rat transplantable hepatoma and human primarily hepatomas, in cell lines derived from these tissues and in human fetal liver

Cancer Res.

Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism

Biochemistry

Thymidylate synthetase-substrate complex formation

Molec. cell. Biochem.

Effect of 5-fluorouracil substitution on the self-splicing activity of Tetrahymena of ribosomal RNA

Cancer Res.

Modulation of 5-fluoro-2′-deoxyuridine response by folinic acid in human colonic tumor cell lines: The role of thymidylate sythase

Molec. Pharmac.

Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells

Canceer Res.

Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells

Cancer Res.

Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil on the activity and site of action of 5-fluorouracil

Cancer Res.

5-fluorouracil-methotrexate synergy: Enhancement of 5-fluorodeoxy-uridylate binding to thymidylate synthase by dihydropteroylpolyglutamates

Dissociation of thymidylate biosynthesis from DNA biosynthesis by 5-fluoro-2′-deoxyuridine and 5,8-dideazaisofolic acid

Cancer Res.

Analysis of the effect of 5-fluorouracil on the synthesis and translation of polysomal poly(A)RNA from Ehrlich ascites cells

Molec. Pharmac.